Screening for Fragile X Syndrome (Murray et al.) - NIHR Journals ...
Screening for Fragile X Syndrome (Murray et al.) - NIHR Journals ...
Screening for Fragile X Syndrome (Murray et al.) - NIHR Journals ...
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
He<strong>al</strong>th Technology Assessment 1997; Vol. 1: No. 4Chapter 6Prev<strong>al</strong>enceStudies of prev<strong>al</strong>ence f<strong>al</strong>l into two distinctgroups. In one group of studies, the investigatorsstudied the cases of fragile X syndromefound in institutions. In the absence of in<strong>for</strong>mationon the proportion of affected individu<strong>al</strong>swho are institution<strong>al</strong>ised, these studiescannot be used to estimate a population prev<strong>al</strong>ence.Non<strong>et</strong>heless, they do <strong>al</strong>low an estimateof the frequency of the disorder among individu<strong>al</strong>swith ment<strong>al</strong> handicap, which is useful<strong>for</strong> case-finding (see page 27). In a secondgroup of studies either multiple sources or asystematic m<strong>et</strong>hod of ascertainment was usedto obtain a more compl<strong>et</strong>e yield of cases in thewhole of a defined population.BiasThere is likely to be marked b<strong>et</strong>ween-studyvariability in the estimated prev<strong>al</strong>ence of fragileX syndrome owing to important differences instudy design. Those studies which are basedon a cytogen<strong>et</strong>ic diagnosis of fragile X syndromewill tend to yield higher estimates of prev<strong>al</strong>enc<strong>et</strong>han those using DNA m<strong>et</strong>hods. Studies thatinclude fem<strong>al</strong>es will tend to underestimateprev<strong>al</strong>ence if diagnostic testing is restrictedto institutions and speci<strong>al</strong> education<strong>al</strong> units.The relatively large number of mild cases mayescape d<strong>et</strong>ection. Studies that include a disproportionatenumber of children will <strong>al</strong>so tendto yield relatively low estimates. Diagnosis willbe delayed in individu<strong>al</strong>s in whom the clinic<strong>al</strong>features of fragile X syndrome are not apparentuntil puberty; indeed, in some individu<strong>al</strong>s theintellectu<strong>al</strong> deficit may not be noticed untilthey are of secondary school age.Frequency in thement<strong>al</strong>ly handicappedThe frequency of fragile X syndrome in institution<strong>al</strong>isedm<strong>al</strong>es was examined in ten studies (Table 8).Of the 2019 m<strong>al</strong>es tested in <strong>al</strong>l the studies combined,6% were found to be affected. However, thefrequency varied greatly b<strong>et</strong>ween studies and theh<strong>et</strong>erogeneity may mean that the over<strong>al</strong>l frequencyis not a reliable estimate of the true rate. TheTABLE 8 Frequency of fragile X syndrome among m<strong>al</strong>esin institutions: results of ten studiesStudy Selection Number <strong>Fragile</strong> Xcriteria * (%)Finland UA 150 6 (4)Kähkönen <strong>et</strong> <strong>al</strong>, 1983Germany All 242 15 (6)Froster-Iskenius<strong>et</strong> <strong>al</strong>, 1983USA, Boston UA 44 6 (14)Paika <strong>et</strong> <strong>al</strong>, 1984Belgium UA 354 57 (16)Fryns <strong>et</strong> <strong>al</strong>, 1984cJapan All 305 11 (4) †Arinami <strong>et</strong> <strong>al</strong>, 1986Hofstee <strong>et</strong> <strong>al</strong>, 1994UK UA 100 7 (7)Primrose <strong>et</strong> <strong>al</strong>, 1986USA, Colorado UA 267 7 (3)Hagerman <strong>et</strong> <strong>al</strong>,1988aSicily All 155 12 (8)Neri <strong>et</strong> <strong>al</strong>, 1988USA,Tennessee UA 201 4 (2)Butler & Singh, 1993Poland All 201 6 (3) †Mazurczak <strong>et</strong> <strong>al</strong>, 1996All 2019 131 (6)† All m<strong>al</strong>es were tested except in studies selecting those withunknown ment<strong>al</strong> impairment of a<strong>et</strong>iology (UA).* Confirmed by DNA an<strong>al</strong>ysis.variability was due to a number of differences instudy design; viz:• admission patterns <strong>for</strong> the institution• compl<strong>et</strong>eness of ascertainment due topatient and parent<strong>al</strong> non-compliance withdiagnostic testing• selection criteria <strong>for</strong> testing (e.g. in somestudies only those with typic<strong>al</strong> features of fragileX syndrome were tested, while in otherseveryone was tested)• definition of the denominator population.21